According to the research report, the global compounding pharmacy market size is expected to touch USD 28.19 Billion by 2032, from USD 14.92 Billion in 2022, growing with a significant CAGR of 6.57% from 2023 to 2032.
Key Takeaways:
- North America is expected to dominate the market during the forecast period.
- By therapeutic area, the pain management segment is expected to dominate the market over the forecast period.
- By route of administration, the oral segment is expected to hold the largest revenue share over the forecast period.
- By distribution channel, the hospital pharmacy segment is expected to dominate the market over the forecast period.
The compounding pharmacy report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global compounding pharmacy in conjunction with the geographical landscape of this vertical have also been included in this report.
The report offers intricate dynamics about different aspects of the global compounding pharmacy market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global compounding pharmacy during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/3185
This study covers a detailed segmentation of the global compounding pharmacy market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global compounding pharmacy market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.
Key Players
- Fresenius Kabi
- Fagron NV
- B. Braun Medical Inc.
- Rx3 Compounding Pharmacy
- Clinigen Group PLC
- Dougherty's Pharmacy, Inc.
- Lorraine's Pharmacy
- Wedgewood Pharmacy
- Institutional Pharmacy Solutions
- Mcguff compounding pharmacy services
Market Segmentation
By Therapeutic Area
- Pain Management
- Hormone Replacement
- Dermal Disorders
- Nutritional Supplements
- Others
By Route of Administration
- Oral
- Topical
- Parenteral
- Others
By Application
- Pediatric
- Geriatric
- Adult
- Veterinary
By Compounding Type
- Pharmaceutical Dosage Alteration (PDA)
- Pharmaceutical Ingredient Alteration (PIA)
- Currently Unavailable Pharmaceutical Manufacturing (CUPM)
- Others
By Sterility
- Sterile
- Non-sterile
By Distribution Channel
- Compounding Pharmacy
- Hospital Pharmacy
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Research Methodology
The research methodology adopted by analysts for compiling the global compounding pharmacy report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global compounding pharmacy market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Compounding Pharmacy Market
5.1. COVID-19 Landscape: Compounding Pharmacy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Compounding Pharmacy Market, By Therapeutic Area
8.1. Compounding Pharmacy Market, by Therapeutic Area, 2023-2032
8.1.1. Pain Management
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Hormone Replacement
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Dermal Disorders
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Nutritional Supplements
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Compounding Pharmacy Market, By Route of Administration
9.1. Compounding Pharmacy Market, by Route of Administration, 2023-2032
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Topical
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Parenteral
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Compounding Pharmacy Market, By Application
10.1. Compounding Pharmacy Market, by Application, 2023-2032
10.1.1. Pediatric
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Geriatric
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Adult
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Veterinary
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Compounding Pharmacy Market, By Compounding Type
11.1. Compounding Pharmacy Market, by Compounding Type, 2023-2032
11.1.1. Pharmaceutical Dosage Alteration (PDA)
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Pharmaceutical Ingredient Alteration (PIA)
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Currently Unavailable Pharmaceutical Manufacturing (CUPM)
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Compounding Pharmacy Market, By Sterility
12.1. Compounding Pharmacy Market, by Sterility, 2023-2032
12.1.1. Sterile
12.1.1.1. Market Revenue and Forecast (2020-2032)
12.1.2. Non-sterile
12.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 13. Global Compounding Pharmacy Market, By Distribution Channel
13.1. Compounding Pharmacy Market, by Distribution Channel, 2023-2032
13.1.1. Compounding Pharmacy
13.1.1.1. Market Revenue and Forecast (2020-2032)
13.1.2. Hospital Pharmacy
13.1.2.1. Market Revenue and Forecast (2020-2032)
13.1.3. Others
13.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 14. Global Compounding Pharmacy Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.1.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.1.3. Market Revenue and Forecast, by Application (2020-2032)
14.1.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.1.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.1.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.1.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.1.7.3. Market Revenue and Forecast, by Application (2020-2032)
14.1.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.1.8. Market Revenue and Forecast, by Sterility (2020-2032)
14.1.8.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.1.9.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.1.9.3. Market Revenue and Forecast, by Application (2020-2032)
14.1.9.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.1.10. Market Revenue and Forecast, by Sterility (2020-2032)
14.1.11. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.2.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.2.3. Market Revenue and Forecast, by Application (2020-2032)
14.2.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.2.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.2.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.2.8.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.2.8.3. Market Revenue and Forecast, by Application (2020-2032)
14.2.9. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.2.10. Market Revenue and Forecast, by Sterility (2020-2032)
14.2.10.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.2.11.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.2.11.3. Market Revenue and Forecast, by Application (2020-2032)
14.2.12. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.2.13. Market Revenue and Forecast, by Sterility (2020-2032)
14.2.14. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.2.15.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.2.15.3. Market Revenue and Forecast, by Application (2020-2032)
14.2.15.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.2.16. Market Revenue and Forecast, by Sterility (2020-2032)
14.2.16.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.2.17.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.2.17.3. Market Revenue and Forecast, by Application (2020-2032)
14.2.17.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.2.18. Market Revenue and Forecast, by Sterility (2020-2032)
14.2.18.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.3.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.3.3. Market Revenue and Forecast, by Application (2020-2032)
14.3.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.3.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.3.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.3.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.3.7.3. Market Revenue and Forecast, by Application (2020-2032)
14.3.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.3.8. Market Revenue and Forecast, by Sterility (2020-2032)
14.3.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.3.10.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.3.10.3. Market Revenue and Forecast, by Application (2020-2032)
14.3.10.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.3.11. Market Revenue and Forecast, by Sterility (2020-2032)
14.3.11.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.3.12.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.3.12.3. Market Revenue and Forecast, by Application (2020-2032)
14.3.12.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.3.12.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.3.12.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.3.13.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.3.13.3. Market Revenue and Forecast, by Application (2020-2032)
14.3.13.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.3.13.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.3.13.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.4.3. Market Revenue and Forecast, by Application (2020-2032)
14.4.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.4.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.4.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.4.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.4.7.3. Market Revenue and Forecast, by Application (2020-2032)
14.4.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.4.8. Market Revenue and Forecast, by Sterility (2020-2032)
14.4.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.4.10.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.4.10.3. Market Revenue and Forecast, by Application (2020-2032)
14.4.10.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.4.11. Market Revenue and Forecast, by Sterility (2020-2032)
14.4.12. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.4.13.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.4.13.3. Market Revenue and Forecast, by Application (2020-2032)
14.4.13.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.4.13.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.4.13.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.4.14.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.4.14.3. Market Revenue and Forecast, by Application (2020-2032)
14.4.14.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.4.14.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.4.14.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.5.3. Market Revenue and Forecast, by Application (2020-2032)
14.5.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.5.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.5.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.5.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.5.7.3. Market Revenue and Forecast, by Application (2020-2032)
14.5.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.5.8. Market Revenue and Forecast, by Sterility (2020-2032)
14.5.8.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.5.9.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.5.9.3. Market Revenue and Forecast, by Application (2020-2032)
14.5.9.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.5.9.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 15. Company Profiles
15.1. Fresenius Kabi
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Fagron NV
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. B. Braun Medical Inc.
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Rx3 Compounding Pharmacy
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Clinigen Group PLC
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Dougherty's Pharmacy, Inc.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Lorraine's Pharmacy
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Wedgewood Pharmacy
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Institutional Pharmacy Solutions
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Mcguff compounding pharmacy services
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments